Galinpepimut-s clinical trials
Also written SLS-001.
How each study uses galinpepimut-s is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2019 | 2 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 1
Sellas Life Sciences Group (5) · 3D Medicines (1) · Memorial Sloan Kettering Cancer Center (1)
Often tested with
Tested in the same studies.
Granulocyte-Macrophage Colony-Stimulating Factor (3) · Monatide (IMS 3015) (1)
Studies
Open first, then newest update. How each study uses galinpepimut-s is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Study of 3D189 in Patients With Hematologic MalignanciesCompletedPhase 13D MedicinesNCT05320809Written as 3D189
- Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2Active, not recruitingPhase 3Sellas Life Sciences GroupNCT04229979Written as Galinpepimut-S
- Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in MesotheliomaCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT04040231Written as Galinpepimut-S
- Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced CancersCompletedPhase 1/2Sellas Life Sciences GroupNCT03761914Written as galinpepimut-S
- WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)CompletedPhase 2Sellas Life Sciences GroupNCT01266083Written as Galinpepimut-S
- Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality TherapyCompletedPhase 2Sellas Life Sciences GroupNCT01265433Written as Galinpepimut-S + Montanide + GM-CSF
- WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell TransplantationCompletedPhase 1/2Sellas Life Sciences GroupNCT01827137Written as Galinpepimut-S
Codes
What other systems call galinpepimut-s · ClinicalTrials.gg INT014267
- UNII (FDA) 12R66419FZGALINPEPIMUT-SOne source FDA
- NCI Thesaurus C161778Galinpepimut-SOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 12R66419FZ | GALINPEPIMUT-S | One source FDA |
| NCI Thesaurus | C161778 | Galinpepimut-S | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.